Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

F2G raises $60.8M to get new class of antifungal to market

Venture round could carry ‘breakthrough’ antifungal to 2022-23 launch 

By stephen hansen, associate editor
August 13, 2020 1:18 AM UTC

F2G thinks its latest round of venture funding should be enough to carry its lead product onto the market, where it could become the first new antifungal in two decades, according to the company.

New investor Cowen Healthcare Investments led the $60.8 million round for F2G Ltd., which told BioCentury that the new capital would finance completion of a Phase IIb trial of olorofim (formerly F901318), as well as a Phase III program and the therapy’s launch. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

F2g Ltd.